Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain

Crosignani PG, P. G. Crosignani, A Luciano, Luciano A, Anthony A. Luciano, Ray A, Amrit Ray, A Ray, Bergqvist A, Agneta Bergqvist, A Bergqvist
Human Reproduction · 2005 · vol. 21(1) , pp. 248–256 · doi:10.1093/humrep/dei290 · PMID:16176939 · W2169590550
RCT OA: bronze CC0 ⤵ 132 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Subcutaneous depot medroxyprogesterone acetate (104 mg every 3 months) demonstrated equivalent pain reduction to leuprolide for endometriosis and showed significantly less bone mineral density loss.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: A clinical study compared efficacy and safety of depot medroxyprogesterone acetate (DMPA) with leuprolide for endometriosis-associated pain. METHODS: This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months), with 12 months post-treatment follow-up. Endpoints included patient response to treatment in five signs/symptoms (dysmenorrhoea, dyspareunia, pelvic pain, pelvic tenderness, induration) and changes in bone mineral density (BMD) and productivity at 6 and 18 months. RESULTS: DMPA-SC 104 and leuprolide produced equivalent (P < 0.02) reductions in at least four pain categories and significant (P < 0.001) improvements in composite score at months 6 and 18. At month 6, reductions in total hip and lumbar spine BMD were significantly less (P < 0.001) with DMPA-SC 104 versus leuprolide. BMD returned to pre-treatment levels 12 months post-treatment in the DMPA-SC 104 but not the leuprolide group. Total productivity also significantly (P < or = 0.05) improved in both groups at 6 and 18 months. CONCLUSIONS: DMPA-SC 104 reduces endometriosis-associated pain as effectively as leuprolide and improves productivity with significantly less BMD decline.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_paindysmenorrheadyspareunia

MeSH descriptors

Antineoplastic Agents, Hormonal Contraceptive Agents, Female Endometriosis Fertility Agents, Female Leuprolide Medroxyprogesterone Acetate Pelvic Pain Uterine Diseases Administration, Cutaneous Administration, Cutaneous Adult Adult Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Bone Density Bone Density Contraceptive Agents, Female Contraceptive Agents, Female Contraceptive Agents, Female

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (44)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-19T06:17:24.038039+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:03:24.829172+00:00
License: CC0 · commercial use OK